Tag: chimeric antigen receptor (CAR) T-cell therapy

Genetically engineered T-cell therapies, such as chimeric antigen receptor T-cells (CAR T-cells), have been approved for the treatment of hematologic malignancies, however, there are limited data to support this approach in the management of epithelial cancers. Human papillomavirus (HPV)-associated epithelial cancers express viral E6 and E7 oncoproteins, which are...
Pregnancy duration and endometrial cancer risk: nationwide cohort study Full-term pregnancies are strongly associated with a reduced risk of endometrial cancer. Whether this protective association is driven by fecundity, a specific process that occurs during pregnancy, or cumulative number of months pregnancy, however, is unknown. In this cohort study, 2,311,332...
1. bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) proteins, was shown to achieve objective response rates amongst a majority of 33 patients with refractory or relapsed multiple myeloma participating in a phase 1 safety trial.  2. A majority of patients in this study...
1. bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) proteins, was shown to achieve objective response rates amongst a majority of 33 patients with refractory or relapsed multiple myeloma participating in a phase 1 safety trial. 2. A majority of patients in this...